Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals · CIK 0000078003
$30.42
+1.91% · live
Updated
$172.40B market value
From PFIZER INC's FY2025 10-K, filed Feb 26, 2026 · read the filing
PFIZER develops and makes medicines. It took in $62.58B last year, which makes it a very large company. Of every dollar it sells, about 12 cents is left as profit.
The financial picture is led by profitability and accounting, with debt worth watching, while growth remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Generally healthy, with a few things to watch.
From PFIZER INC's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Gross margin
71.9% → 74.3%
Free cash flow
$9.84B → $9.07B
Long-term debt
$57.41B → $61.64B
Cash
$1.04B → $1.14B
Measured against FY2024, from the 10-K filed Feb 26, 2026
Improved: +2.4 pts
71.9% to 74.3%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
How the latest move compares (quote live), and what was published around it
PFE rose 1.91% on the latest quote. The average Health Care company tracked here moved +1.61%, and the S&P 500 −1.04%. That is in line with its sector and 3.0 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 33 analysts covering this company, as of . Their views, not this site's.
Of 33 analysts publishing on this company, 5 say strong buy, 8 say buy, 18 say hold, 1 say sell and 1 say strong sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 12 cents of every dollar of sales as profit, earning $7.77B last year.
No. Sales shrank 1.6% last year.
Manageable, but notable. Clearing its debt would take about 5.4 years of cash flow. For every $1 it owes, it owns $1.71 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $7.77B and generated $11.70B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 26, 2026Filing for FY2025 | FY202410-K · Feb 27, 2025Filing for FY2024 | FY202310-K · Feb 27, 2025Filing for FY2023 | FY202210-K · Feb 22, 2024Filing for FY2022 | FY202110-K · Feb 22, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $62.58B | $63.63B | $50.91B | $91.79B | $73.64B | −1.6% |
| Cost of revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | −10.0% |
| Gross profit | $46.51B† | $45.78B† | $25.96B† | $57.45B† | $42.81B† | +1.6% |
| Gross marginGross profit ÷ revenueWhat is this? | 74.3% | 71.9% | 51.0% | 62.6% | 58.1% | +2.4 pts |
| Selling, general and administrative | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B | −6.4% |
| Interest expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | −13.6% |
| Income before tax | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | −6.3% |
| Net income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | −3.2% |
| Net marginNet income ÷ revenueWhat is this? | 12.4% | 12.6% | 4.2% | 34.2% | 29.8% | −0.2 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $1.37 | $1.42 | $0.3771 | $5.58 | $3.94 | −3.6% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| PFEPFIZER INC · this page | 7.0/10 | 6/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Nothing recent
No insider trades, pending-sale notices or 5% stake filings from PFE in the last few months. That is the ordinary case, not a gap.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Profit margin −21.5 pts · Profit turned negative · Earnings per share turned negative — against Q2 FY2025
Read the filingPublished results
Read the filingWrite down why you are following PFIZER INC, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
Yahoo ·
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Yahoo ·
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
Yahoo ·
Biohaven’s previously rejected rare disease drug to get fresh FDA review
Yahoo ·
Pfizer’s High Dividend Yield May Be a Warning. Here’s How Merck Compares
Yahoo ·
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from PFE's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 26, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 7.0 | 6/9 | 10-K, filed Feb 26, 2026 |
| FY2024 | 9.0 | 9/9 | 10-K, filed Feb 27, 2025 |
| FY2023 | 5.0 | 4/9 | 10-K, filed Feb 22, 2024 |
| FY2022 | 10.0 | 7/9 | 10-K, filed Feb 23, 2023 |
| FY2021 | 9.0 | 8/9 | 10-K, filed Feb 24, 2022 |
| FY2020 | 8.7 | 6/9 | 10-K, filed Feb 25, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
2.12
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.52
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: -7.7%
$9.84B to $9.07BNotable
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: +7.4%
$57.41B to $61.64BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +9.5%
$1.04B to $1.14BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: -9.6%
$2.91B to $2.63BNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 4, 2026 — read it.
Deteriorated: turned negative
$2.91B to -$248.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −21.5 pts
19.9% to -1.6%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$0.51 to -$0.04Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -40.4%
$1.64B to $976.0MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: −1.4 pts
74.2% to 72.8%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: +5.2%
$57.50B to $60.49BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 4, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: turned negative
$2.69B to -$248.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −20.2 pts
18.6% to -1.6%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$0.47 to -$0.04Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -42.7%
$1.70B to $976.0MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: −2.7 pts
75.4% to 72.8%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
6 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.7% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 19.4x — investors pay $19.4 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| -1.6% |
| 12.4% |
| 22.19x |
| 1.40x |
| LLYELI LILLY & Co | 9.0/10 | 7/9 | 44.7% | 31.7% | 60.03x | 3.24x |
|---|
| JNJJOHNSON & JOHNSON | 9.0/10 | 4/9 | 6.0% | 28.5% | 24.04x | 1.44x |
|---|
| MRKMerck & Co., Inc. | 9.0/10 | 5/9 | 1.3% | 28.1% | 20.38x | 1.60x |
|---|
| BMYBRISTOL MYERS SQUIBB CO | 8.0/10 | 9/9 | -0.2% | 14.6% | 18.12x | 3.87x |
|---|
| ZTSZoetis Inc. | 9.0/10 | 7/9 | 2.3% | 28.2% | 13.04x | 3.64x |
|---|
| VTRSViatris Inc | 4.0/10 | 5/9 | -3.0% | -24.7% | — | 1.53x |
|---|
| Median of peers | 9.0/10 | — | 1.8% | 28.2% | 20.38x | 2.42x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Made a Regulation FD disclosure
Had a director or senior officer leave or join
Read the filingQuarterly report for Q1 FY2026
Revenue +5.4% · Profit margin −3.0 pts · Gross margin −3.8 pts — against Q1 FY2025
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Gross margin +2.4 pts · Free cash flow -7.7% · Long-term debt +7.4% — against FY2024
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingReported another event
Read the filingReported another event
Read the filingQuarterly report for Q3 FY2025
Revenue -5.9% · Profit margin −4.0 pts · Profit -20.7% — against Q3 FY2024
Read the filingPublished results
Read the filingQuarterly report for Q2 FY2025
Revenue +10.3% · Profit margin +19.6 pts · Profit +6997.6% — against Q2 FY2024
Read the filingPublished results
Read the filingReported another event
Read the filingQuarterly report for Q1 FY2025
Revenue -7.8% · Free cash flow +358.8% · Cash +98.9% — against Q1 FY2024
Read the filingAnnounced restructuring or exit costs · Published results
Read the filingPrimary sources and further research